Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma

Abstract The RATIONALE-306 study revealed that patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC) could benefit from treatment with tislelizumab plus chemotherapy. This study aimed to evaluate the cost-effectiveness of tislelizumab plus chemotherapy for treating OSCC fro...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Li Zhang, Henghai Su, Xueyan Liang, Xiaoyu Chen, Yan Li
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2024-07-01
Serija:	Scientific Reports
Teme:	Cost-effectiveness analysis Tislelizumab Oesophageal squamous cell carcinoma RATIONALE-306 Chemotherapy
Online dostop:	https://doi.org/10.1038/s41598-024-68399-3
Oznake:	Označite Brez oznak, prvi označite!